by Karen O'Hanlon Cohrt | Jul 30, 2026 | Cell Culture Techniques, Trends
Key Takeaways Overcoming Sample Constraints: Traditional assays like ELISA often struggle with ultra-low volume samples or low-abundance secreted biomarkers. The Power of Signal Amplification: Immuno-qPCR (qIPCR) links antibody specificity to DNA barcode...
by Karen O'Hanlon Cohrt | Sep 14, 2026 | Trends
Biomarker measurements provide valuable information about biological processes, disease and treatment response, but they represent selected features of a much more complex biological system. Many biomarker assays provide a time-fixed snapshot. DNA, RNA and protein...
by Karen O'Hanlon Cohrt | Jul 1, 2026 | Trends
Welcome back to our series on NAMs. So far, we have looked at how model choice depends on the scientific question, and where NAMs can support nonclinical drug development. In this article, we move beyond pharmaceuticals to look at how human cell-based NAMs could also...
by Karen O'Hanlon Cohrt | Jun 9, 2026 | Trends
In our last article, we explored how selecting the right model depends on the scientific question and the stage of research. We summarized the strengths and limitations of animal- and human-derived cells and discussed why moving toward more human-relevant models is...
by Karen O'Hanlon Cohrt | Mar 22, 2026 | Disease Models, Trends
It is no secret that cell-based models are the backbone of modern drug discovery. For decades, researchers have used animal-based models including cells and whole animals to investigate mechanisms of disease, screen compounds, and support preclinical research. Over...
by Karen O'Hanlon Cohrt | Oct 6, 2025 | Disease Models, Trends
In a previous article we introduced keratinocytes and looked at their biological functions and subtypes. Here, we explore some of the main reasons researchers study keratinocytes and the various approaches used. We focus on 2D assay formats, outlining their advantages...
